An investigation of the stability of meropenem in elastomeric infusion devices

References

• Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018;37(8):1411–1419. doi:10.1007/s10096-018-3260-429675787
   PubMed Web of Science ®Google Scholar
• Zhao H, Gu J, Lyu J, et al. Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study. Chin Med J. 2017;130(10):1139–1145. doi:10.4103/0366-6999.20585928485312
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother. 2003;52(3):518–521. doi:10.1093/jac/dkg48612917242
   PubMed Web of Science ®Google Scholar
• Keil S, Wiedemann B. Antimicrobial effects of continuous versus intermittent administration of carbapenem antibiotics in an in vitro dynamic model. Antimicrob Agents Chemother. 1997;41(6):1215–1219. doi:10.1128/AAC.41.6.12159174173
   PubMed Web of Science ®Google Scholar
• Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142–150. doi:10.1093/jac/dkp13919398460
   PubMed Web of Science ®Google Scholar
• Saillen L, Arensdorff L, Moulin E, et al. Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practicing predominantly self-administration of antibiotics with elastomeric pumps. Eur J Clin Microbiol Infect Dis. 2017;36(8):1387–1392. doi:10.1007/s10096-017-2944-528283831
   PubMed Web of Science ®Google Scholar
• Chapman ALN. Outpatient parenteral antimicrobial therapy. BMJ. 2013;346:f1585. doi:10.1136/bmj.f116423532865
   PubMed Web of Science ®Google Scholar
• Chapman ALN, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother. 2012;67(5):1053–1062. doi:10.1093/jac/dks00322298347
   PubMed Web of Science ®Google Scholar
• Mitchell ED, Czoski Murray C, Meads D, et al. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review. BMJ. 2017;7(4):e013560.
   PubMed Web of Science ®Google Scholar
• Manning L, Wright C, Ingram PR, et al. Continuous infusion of meropenem in ambulatory care: clinical efficacy, safety and stability. PLoS One. 2014;9(7):1–7:e102023. doi:10.1371/journal.pone.0102023
   Web of Science ®Google Scholar
• Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65(5):1073–1075. doi:10.1093/jac/dkq04420176578
   PubMed Web of Science ®Google Scholar
• Franceschi L, Cojutti P, Baraldo M, Pea F. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014;36(5):674–676. doi:10.1097/FTD.000000000000005424637698
   PubMed Web of Science ®Google Scholar
• Viaene E, Chanteux H, Servais H, Mingeot-Leclercq M, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46(8):2327–2332. doi:10.1128/AAC.46.8.2327-2332.200212121900
   PubMed Web of Science ®Google Scholar
• Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm. 1997;54(4):412–421. doi:10.1093/ajhp/54.2.1719043564
   PubMed Web of Science ®Google Scholar
• Mendez ASL, Steppe M, Schapoval EES. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal. 2003;33(5):947–954. doi:10.1016/S0731-7085(03)00366-214656585
   PubMed Web of Science ®Google Scholar
• Takasu Y, Yoshida M, Tange M, Asahara K, Uchida T. Prediction of the stability of meropenem in intravenous mixtures. Pharm Bull. 2015;63(4):248–254. doi:10.1248/cpb.c14-00516
   Google Scholar
• United Stats Pharmacopeia and National Formulary (USP41-NF36) [internet] 41st ed. Rockville: United States Pharmacopeial Convention; 2016 Chromatography Available from: https://online.uspnf.com/uspnf/document/GUID-6C3DF8B8-D12E-4253-A0E7-6855670CDB7B_1_en-US. Accessed 130, 2019.
   Google Scholar
• Mendez ASL, Dalomo J, Steppe M, Schapoval EES. Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample. J Pharm Biomed Anal. 2006;41(4):1363–1366. doi:10.1016/j.jpba.2006.02.01716533586
   PubMed Web of Science ®Google Scholar
• Mendez A, Chagastelles P, Palma E, Nardi N, Schapoval E. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm. 2008;350(1–2):95–102. doi:10.1016/j.ijpharm.2007.08.02317904314
   PubMed Web of Science ®Google Scholar
• Grant EM, Zhong MK, Ambrose PG, Nicolau DP, Nightingale CH, Quintiliani R. Stability of meropenem in a portable infusion device in a cold pouch. Am J Health Syst Pharm. 2000;57(10):992–995. doi:10.1093/ajhp/57.suppl_4.S1010832500
   PubMed Web of Science ®Google Scholar
• Bureau of meteorology. Climate statistics for Australian locations [Internet] 2019 Available from: http://www.bom.gov.au/climate/averages/tables/cw_009225.shtml. Accessed 210, 2019.
   Google Scholar
• British Pharmacopoeia [Internet] Vol. 1 London: Medicines and Healthcare products Regulatory Agency; 2019 Sodium Carbonate Available from: https://www-pharmacopoeia-com.dbgw.lis.curtin.edu.au/bp-2019/monographs/sodium-carbonate.html?date=2019-01-01&text=sodium+carbonate. Accessed 212, 2019.
   Google Scholar
• Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004;26(4):493–501. doi:10.1016/S0149-2918(04)90051-315189746
   PubMed Web of Science ®Google Scholar
• Prescott WA, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. P & T. 2011;36(11):723–763.22346306
   PubMedGoogle Scholar
• Meropenem Ranbaxy. In MIMS Online Database [Internet] MIMS Australia; 2014 Available from: https://www-mimsonline-com-au.dbgw.lis.curtin.edu.au/Search/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=meromerom&PreviousPage=~/Search/QuickSearch.aspx&SearchType=&ID=93950001_2. Accessed 215, 2019.
   Google Scholar